Study, year | Total sample size | Mean age (linezolid/vancomcyin) | Type of infection | Intubation (%) at baseline (linezolid/vancomycin) | Mean days of therapy (linezolid/vancomycin) | Linezolid arm (Gram-negative coverage) | Vancomycin arm (Gram-negative coverage) | Primary outcome | Jadad score |
---|---|---|---|---|---|---|---|---|---|
Rubinstein E (2001)20 | 396 | 63/61 | Hospital-acquired pneumonias | 57.1/57.5 | 9.6/8.9 | Linezolid+aztreonam | Vancomycin+aztreonam | CR and ME at TOC | 4 |
Stevens DL (2002)21 | 460 | 64/60 | MRSA infections, including hospital-acquired pneumonias | NR/NR | 12.6/11.3 | Linezolid+aztreonam or gentamicin | Vancomycin+aztreonam or gentamicin | CR and ME at TOC | 3 |
Kaplan SL (2003)22 | 316 | 2.2/2.9 | Gram-positive infections, including hospital-acquired pneumonias | NR/NR | 11.3/12.2 | Linezolid+aztreonam or gentamicin | Vancomycin+aztreonam or gentamicin | CR and ME at TOC | 3 |
Wunderink R (2003)23 | 623 | 63/62 | Hospital-acquired pneumonias | NR/NR | 9.5/9.4 | Linezolid+aztreonam | Vancomycin+aztreonam | CR and ME at TOC | 3 |
Jaksic B (2006)24 | 605 | 48/47 | Neutropenic fever, including hospital-acquired pneumonias | NR/NR | 11.4/11.5 | Linezolid+Gram-negative coverage | Vancomycin+Gram-negative coverage | CR and ME at TOC | 4 |
Kohno S (2007)25 | 151 | 68/67 | MRSA infections, including hospital-acquired pneumonias | NR/NR | 10.9/10.6 | Linezolid+aztreonam or gentamicin | Vancomycin+aztreonam or gentamicin | CR and ME at TOC | 3 |
Wunderink R (2008)26 | 149 | 56/55 | MRSA hospital-acquired pneumonias | 100/100 | 10.8/11.5 | Linezolid+Gram-negative coverage | Vancomycin+Gram-negative coverage | CR and ME at FUV | 3 |
Lin D (2008)19 | 142 | 56.3/59.6 | Gram-positive infections, including hospital-acquired pneumonias | 5.6/11.3 | 12.2/10.7 | Linezolid+aztreonam | Vancomycin+aztreonam | CR at FUV and EOT | 3 |
Wunderink R (2012)10 | 1184 | 60.7/61.6 | MRSA hospital-acquired pneumonias | 60.5/66.5 | 10/10 | Linezolid+Gram-negative coverage | Vancomycin+Gram-negative coverage | CR at EOS | 4 |
CON, control; CR, clinical response; EOT: end of therapy; EOS, end of study; FUV, follow-up visit; MRSA, methicillin resistant Staphylococcus aureus; ME, microbiological eradication; NR, not reported; TRE, treatment; TOC, test of cure visit.